Proteon Therapeutics Inc (NASDAQ:PRTO) has been assigned an average recommendation of “Hold” from the nine ratings firms that are presently covering the stock, reports. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $3.33.

PRTO has been the subject of several recent research reports. Zacks Investment Research lowered shares of Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 18th. HC Wainwright reaffirmed a “hold” rating and set a $2.30 target price on shares of Proteon Therapeutics in a report on Wednesday, November 8th. Robert W. Baird reaffirmed a “hold” rating and set a $2.00 target price on shares of Proteon Therapeutics in a report on Friday, November 10th. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Proteon Therapeutics in a report on Wednesday, August 16th.

Proteon Therapeutics (NASDAQ PRTO) traded down $0.03 during trading hours on Thursday, hitting $1.85. 42,279 shares of the stock traded hands, compared to its average volume of 107,070. Proteon Therapeutics has a 52-week low of $1.10 and a 52-week high of $2.75.

In related news, Director James E. Flynn purchased 110,557 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was bought at an average price of $1.75 per share, with a total value of $193,474.75. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 36.30% of the stock is currently owned by insiders.

A hedge fund recently bought a new stake in Proteon Therapeutics stock. RA Capital Management LLC purchased a new position in Proteon Therapeutics Inc (NASDAQ:PRTO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up about 0.2% of RA Capital Management LLC’s portfolio, making the stock its 22nd biggest holding. RA Capital Management LLC owned approximately 7.59% of Proteon Therapeutics at the end of the most recent reporting period. 50.12% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Proteon Therapeutics Inc (PRTO) Given Consensus Rating of “Hold” by Brokerages” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at

About Proteon Therapeutics

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with's FREE daily email newsletter.